Diversified Trust Co increased its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 204.8% in the third quarter, Holdings Channel reports. The firm owned 33,326 shares of the medical equipment provider’s stock after buying an additional 22,391 shares during the quarter. Diversified Trust Co’s holdings in Boston Scientific were worth $1,455,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Aberdeen Group plc increased its stake in shares of Boston Scientific by 3.5% in the 3rd quarter. Aberdeen Group plc now owns 3,175,308 shares of the medical equipment provider’s stock valued at $138,602,000 after acquiring an additional 108,682 shares during the last quarter. Moors & Cabot Inc. raised its position in shares of Boston Scientific by 235.7% in the 3rd quarter. Moors & Cabot Inc. now owns 100,750 shares of the medical equipment provider’s stock valued at $4,398,000 after acquiring an additional 70,740 shares during the period. Compass Capital Management Inc. boosted its stake in Boston Scientific by 16.9% during the 3rd quarter. Compass Capital Management Inc. now owns 1,004,548 shares of the medical equipment provider’s stock worth $43,849,000 after acquiring an additional 145,018 shares during the last quarter. SVB Wealth LLC boosted its stake in Boston Scientific by 457.7% during the 3rd quarter. SVB Wealth LLC now owns 31,868 shares of the medical equipment provider’s stock worth $1,391,000 after acquiring an additional 26,154 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Boston Scientific by 10.8% during the third quarter. Russell Investments Group Ltd. now owns 3,207,330 shares of the medical equipment provider’s stock valued at $140,024,000 after purchasing an additional 311,634 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.
Boston Scientific Price Performance
Shares of BSX opened at $44.33 on Monday. The stock has a 50 day simple moving average of $44.00 and a 200 day simple moving average of $54.50. Boston Scientific Corporation has a 52-week low of $39.57 and a 52-week high of $104.61. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. The firm has a market capitalization of $64.25 billion, a PE ratio of 18.78, a P/E/G ratio of 1.31 and a beta of 0.60.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period last year, the company posted $0.75 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
BSX has been the subject of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. Stifel Nicolaus cut their target price on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, October 26th. Oppenheimer cut shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 29th. Raymond James Financial reissued an “outperform” rating and issued a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $66.00 to $48.00 and set a “buy” rating for the company in a research report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.43.
Check Out Our Latest Report on BSX
Boston Scientific Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Recommended Stories
- Five stocks we like better than Boston Scientific
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
